These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10606174

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. p53 protein and bcl-2 expression in glioblastomas. Pathological correlations in a comprehensive series.
    Ardeleanu C, Ceauşu M, Butur G, Grămadă ZF, Dănăilă L, Hălălău F, Arsene D.
    Rom J Morphol Embryol; 2005; 46(4):275-8. PubMed ID: 16688362
    [Abstract] [Full Text] [Related]

  • 23. Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.
    Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, van Staveren IL, van Geel A, Peeterse HJ, Bonnema J, Berns EM.
    J Pathol; 1999 Oct; 189(2):169-75. PubMed ID: 10547570
    [Abstract] [Full Text] [Related]

  • 24. Proliferative activity (Ki-67), WT p53, Bcl-2 expression and their relationship to the tumor grade, in invasive ductal breast carcinomas.
    Kalogeraki A, Garbagnati F, Santinami M, Zoras O.
    In Vivo; 2002 Oct; 16(2):141-4. PubMed ID: 12073773
    [Abstract] [Full Text] [Related]

  • 25. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ.
    Anticancer Res; 2000 Oct; 20(6B):4221-5. PubMed ID: 11205251
    [Abstract] [Full Text] [Related]

  • 26. Prognostic relevance of p53 protein expression in glioblastoma.
    Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ungersböck K, Rössler K, Budka H, Hainfellner JA.
    Oncol Rep; 2002 Oct; 9(4):703-7. PubMed ID: 12066196
    [Abstract] [Full Text] [Related]

  • 27. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H, Zizi-Sermpetzoglou A, Elemenoglou I, Papatheofanis I, Peros G, Athanasas G, Panousopoulos D.
    Pol J Pathol; 2006 Oct; 57(3):149-59. PubMed ID: 17219742
    [Abstract] [Full Text] [Related]

  • 28. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W.
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [Abstract] [Full Text] [Related]

  • 29. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, Koukourakis MI.
    Anticancer Res; 2001 May; 21(1A):253-9. PubMed ID: 11299743
    [Abstract] [Full Text] [Related]

  • 30. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder].
    Rammeh-Rommani S, Zermani R, Sfaxi M, Chabchoub A, Zouari B, Ayed M, Ben Jilani-Baltagi S.
    Tunis Med; 2007 Jun; 85(6):509-12. PubMed ID: 17644907
    [Abstract] [Full Text] [Related]

  • 31. Expression of apoptotic and proliferation markers in meningiomas.
    Konstantinidou AE, Pavlopoulos PM, Patsouris E, Kaklamanis L, Davaris P.
    J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [Abstract] [Full Text] [Related]

  • 35. [Primary gastric lymphomas. Clinico-pathological study and evaluation of prognostic factors in 65 cases treated surgically].
    Pozzi B, Hotz AM, Feltri M, Cornaggia M, Campiotti L, Bonato M, Pinotti G, Capella C.
    Pathologica; 2000 Dec; 92(6):503-15. PubMed ID: 11234301
    [Abstract] [Full Text] [Related]

  • 36. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder.
    Shrestha ML, Miyake H, Kikutsuji T, Tashiro S.
    J Med Invest; 1998 Aug; 45(1-4):95-102. PubMed ID: 9864969
    [Abstract] [Full Text] [Related]

  • 37. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K.
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [Abstract] [Full Text] [Related]

  • 39. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [Abstract] [Full Text] [Related]

  • 40. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
    Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E.
    Zentralbl Neurochir; 2006 Nov; 67(4):204-9. PubMed ID: 17106834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.